PainChek receives ePAT validation in peer-reviewed study

PainChek ASX PCK ePAT peer-reviewed study
A new peer-reviewed publication in the Journal of Pain Research confirms the accuracy and clinical utility of PainChek in residents in aged care living with moderate to severe dementia.

PainChek’s (ASX: PCK) proprietary pain-detection product has been officially validated by a peer-reviewed study and in added support towards its overall clinical usefulness in detecting pain amongst non-communicative patients.

The study was published in the Journal of Pain Research and looked into the company’s electronic Pain Assessment Tool (ePAT) as a point-of-care solution that uses automated facial analysis in conjunction with other clinical indicators to evaluate the presence and intensity of pain in patients with dementia.

Accurate pain assessment is critical to detect pain and facilitate effective pain management in dementia patients.

The study’s authors aimed to examine clinimetric properties (clinical utility and predictive validity) of PainChek’s ePAT in 34 patients over 400 paired pain assessments.

Using the Abbey Pain Scale as a comparator, ePAT demonstrated excellent performance with high sensitivity, specificity, and accuracy. The study also showed the clinical utility (i.e. clinical usefulness) of PainChek in screening and finding cases of pain among those residents.

PainChek scored highly in all facets of investigation including clinical utility, accuracy, specificity and sensitivity.

As a point of care solution that uses automated facial analysis to help evaluate the presence of pain, ePAT demonstrated excellent performance with high sensitivity (96.1%), high specificity (91.4%) and high clinical accuracy (95.0%).


The study obtained data from dementia patients aged over 65 and who were living at an aged-care facility in excess of 3 months.

The study was conducted in two residential aged-care facilities in Perth, Western Australia, where residents were sampled using purposive convenience strategy.

Predictive validity was measured using accuracy statistics (sensitivity, specificity, positive predictive value, and negative predictive value).

PainChek said that in order to attract widespread clinical use, it is important to confirm both the accuracy and usefulness of the technology compared to existing methods for assessing pain.

“These results, combined with previous studies, support the clinical usefulness of PainChek and further confirms its accuracy in detecting and quantifying pain in non-verbal people, such as those with advanced dementia. The findings also provide clinicians with great confidence for wider uptake of the tool in clinical practice in Australia and internationally,” said Mr Philip Daffas, CEO of PainChek.

    Join Small Caps News

    Get notified of the latest news, interviews and stock alerts.